Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment (Q46307806)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

1 reference

based on heuristic

inferred from title

author name string

Oumar Camara

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Cornelia Jörke

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Ulrike Hammer

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Anne Egbe

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Carola Rabenstein

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Ingo B Runnebaum

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Klaus Hoeffken

7

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Katharina Pachmann

8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

publication date

21 October 2008

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

135

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

643-647

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

https://scigraph.springernature.com/pub.10.1007/s00432-008-0498-8

0 references

Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain metastases: the HER2 paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation of rare circulating tumour cells in cancer patients by microchip technology

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends for Inflammatory Breast Cancer: Is Survival Improving?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival after brain metastases from breast cancer in the trastuzumab era.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB-dependent signaling as a determinant of trastuzumab resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to trastuzumab: a necessary evil or a temporary challenge?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin: mechanisms of action and resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating tumor cells in patients with breast cancer dormancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18936973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-008-0498-8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18936973

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46307806&oldid=2104304348"